Grifols: Better Plasma Economics Can Unlock A Discounted Equity

Grifols is shifting to regional plasma sourcing, aiming for durable cash generation over headline catalysts like a U.S. listing or refinancing. I see improved cash flow as contingent on better sourcing economics, higher network productivity, and incremental plasma protein revenues, not just revenue growth. Despite a 30%+ EV/EBITDA discount to peers, GRFS's value hinges on operational improvements and cash conversion, not simply low multiples.

Seeking Alpha • Sep 17, 2026

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Sep 8, 2026

Oakmark International Small Cap Strategy Q2 2026 Portfolio Update

The portfolio's return was 5.34% (net) for the reporting period. We initiated the following positions: Birkenstock Holding, Dormakaba, Hiab, Reply, SATS Ltd., and Scout24. We eliminated the following positions: Grifols Cl B ADR and Sopra Steria Group.

Seeking Alpha • Aug 15, 2026

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency

BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the completion of the clinical portion of SPARTA (Study of ProlAstin-C Randomized Therapy with Alpha-1 augmentation; NCT01983241), its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin®-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema associated with alpha-1 antitrypsin deficiency (AATD), also known as alpha-1.

GlobeNewsWire • Aug 10, 2026

Grifols Q2 Earnings Call Highlights

Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy.

MarketBeat • Jul 28, 2026

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, GAMUNEX®-C, an intravenous immunoglobulin (IVIg), and XEMBIFY®, its subcutaneous immunoglobulin (SCIg).

GlobeNewsWire • Jul 16, 2026

Oakmark International Small Cap Fund Q2 2026 Portfolio Activity

Oakmark International Small Cap Fund (Investor Class) underperformed the benchmark, the MSCI World ex USA Small Cap Index (net), for the quarter. The European board market remains oversupplied, which is pressuring capital appetite and even service demand as customers run down inventories to free up cash. Hiab provides on-road handling equipment that mounts onto the back of trucks to help customers move heavy goods efficiently and safely.

Seeking Alpha • Jul 16, 2026

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.

Seeking Alpha • Jul 3, 2026

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia.

GlobeNewsWire • Jun 15, 2026

Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst

Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader with global scale and supply security advantages. GRFS trades at a significant valuation discount—forward P/E of 8.42x and price/cash flow of 4.76x—despite robust EBITDA, margin expansion, and improving free cash flow. Recent refinancing pushes major debt maturities to 2028; management guides for 2026 EBITDA margins of at least 25% and €500–€575 million free cash flow pre-dividends.

Seeking Alpha • Jun 4, 2026